[BUY] Pinnacle Investment Management (ASX: PNI) – Flows Hold Up as Private Markets Weigh on Forecasts
Buy rated by institutional sell-side research with an A$18.64 target, 17.8 per cent upside. Pinnacle’s FUM rose A$8.7 billion to A$238.1 billion.

Buy rated by institutional sell-side research with an A$18.64 target, 17.8 per cent upside. Pinnacle’s FUM rose A$8.7 billion to A$238.1 billion.
Hold, sell-side target A$137.40, 2.7 per cent below the A$141.15 share price. Cochlear’s market is recovering while rivals contest its share.
Rated Sell by sell-side research, A$3.50 target: PLS lifts P2000 spend to about A$2.5 billion, pushing free cash flow negative to decade end.
Buy, A$65.70 target, 14.1 per cent upside from A$57.56. Bulks offset a soft copper quarter. Trailing yield 4.2 per cent, fully franked.
Sell: institutional sell-side research targets A$5.90 for Bank of Queensland, 16.5 per cent below A$7.07, as a rate-driven margin lift fades.

RBA statements carry only a faint signal on rate moves, and just 29 per cent of Australians know its employment mandate, new research finds.
The RBA has dropped forward guidance and its hedging language has risen since 2023, coinciding with bigger market surprises on decision days.
Australia’s trimmed mean inflation hit 3.6% in August, the hottest of six major economies, and it’s goods prices driving it, not services.

Buy, US$215.00 target, 14.8 per cent upside. CoreSite data center growth and a US$2.0 billion buyback offset a soft US leasing quarter for AMT.
Buy rated by institutional sell-side research with a US$915.00 target, 37.5 per cent upside, after Teledyne beat and raised 2026 guidance.
Buy, US$670.00 target, 65.4 per cent upside, per institutional sell-side research. AI equipment demand and higher margin targets drive Applied Materials.
Buy rated by institutional sell-side research with a US$32.00 target, 148.6 per cent upside, ahead of Phase 3 wet AMD gene therapy data in 2Q27.
Buy-rated On Holding (ONON); US$44 target, 45.7% upside. Q2’26 adj. EBITDA margin 19.8%, gross margin 65.4%, before any tariff refund.
Defense spending is tilting toward drones, counter-drone systems and munitions on a $1.15 trillion base budget, says institutional sell-side research.
US tech outlook: AI is pushing software spend toward fewer platforms with hard-to-copy data. One example covers more than 240mn US consumers.
Healthcare outlook: new drug launches drive sector growth, with an HIV prevention injection keeping more than 70 per cent of users at six months.
Evolution Mining has completed its acquisition of Carnaby Resources, combining two Australian gold producers through a Court-approved Scheme of Arrangement implemented on 10 November 2026. The transaction marks a significant consolidation in the precious metals sector...
AVID Property Group Holdings has exercised its matching right under its process deed with Ingenia Communities Group, matching Warburg Pincus's non-binding proposal at a price of $5.55 per stapled security. When factoring in Ingenia's potential half-year distribution...
Dicker Data has declared an ordinary quarterly dividend of AUD 0.115 per share for the quarter ended 30 September 2026, fully franked at a 30 percent corporate tax rate. The full franking is significant for Australian resident investors, as it provides attached...
Brambles Limited has priced an €850 million green bond under its European Medium-Term Note programme, marking a significant capital raising activity that demonstrates the...
Monadelphous Group Limited has provided guidance for the half year ending 31 December 2026, forecasting revenue of approximately $1.7 billion and net profit after tax in the...
Finding the best shares to buy on the ASX requires more than just scanning a screener or chasing whatever is up this week. We focus on companies with strong competitive positioning, visible earnings growth, and a catalyst to drive the share price higher over the next...
US equities offer Australian investors access to some of the most innovative and fastest-growing companies in the world. The sheer depth of the American market means there are opportunities across sectors that simply do not exist on the ASX, from cutting-edge biotech...
Dividend investing on the ASX remains one of the most reliable ways to build long-term wealth. Blue chip dividend stocks offer a combination of regular income and capital growth that is difficult to replicate through other strategies, particularly in an environment...
Subscribe today for free and get an alert when we have new research and webinars.
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CAR
MF & Co. Asset Management is a boutique investment firm offering Equity Capital Markets and derivative general advice & trade execution services.
We are specialists in advising and trading in Australian and US Equities, Index & Equity Options and Options on Futures.
Australia
1300 889 603
International
+61 2 8378 7199
M-F: 8am-5pm
Suite 803, Level 8
70 Pitt St, Sydney, NSW 2000